Amneal Insists Generics Are Sustainable As It Eyes Further Growth Avenues
Injectables, Biosimilars Push Set To Add To Respiratory And Naloxone Opportunities
Amneal trumpeted its continued faith in the retail generics market at the recent J.P. Morgan Healthcare Conference, as the US-based player also discussed longer-term goals for its burgeoning injectables and biosimilars portfolios.
